VIGONVITA-B Reports FY2025 Results: Shareholder Loss Widens to 356 Million Yuan

Stock News03-31

VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to the previous year. However, the loss attributable to the company's owners was 356 million yuan, widening by 68.3% year-on-year. The basic loss per share was 2.33 yuan.

During the fiscal year ending December 31, 2025, the company's operating revenue saw substantial growth compared to the prior year. This core growth was primarily driven by two factors. First, following its market approval in July 2025, the company's Class 1 new drug Anweida® (product code: TPN171), used for treating male erectile dysfunction, demonstrated significant market promotion and sales effectiveness, leading to rapid revenue growth. Second, the License-out project for the respiratory syncytial virus (RSV) infection indication of the VV116 dry suspension reached a milestone, resulting in the successful receipt of a milestone payment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166352107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 23:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166352107","market":"hk","top_or_hot":-1,"title":"VIGONVITA-B Reports FY2025 Results: Shareholder Loss Widens to 356 Million Yuan","media":"Stock News","content":"<p>VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to the previous year. However, the loss attributable to the company's owners was 356 million yuan, widening by 68.3% year-on-year. The basic loss per share was 2.33 yuan.</p>\n<p>During the fiscal year ending December 31, 2025, the company's operating revenue saw substantial growth compared to the prior year. This core growth was primarily driven by two factors. First, following its market approval in July 2025, the company's Class 1 new drug Anweida® (product code: TPN171), used for treating male erectile dysfunction, demonstrated significant market promotion and sales effectiveness, leading to rapid revenue growth. Second, the License-out project for the respiratory syncytial virus (RSV) infection indication of the VV116 dry suspension reached a milestone, resulting in the successful receipt of a milestone payment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VIGONVITA-B Reports FY2025 Results: Shareholder Loss Widens to 356 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVIGONVITA-B Reports FY2025 Results: Shareholder Loss Widens to 356 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 23:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to the previous year. However, the loss attributable to the company's owners was 356 million yuan, widening by 68.3% year-on-year. The basic loss per share was 2.33 yuan.</p>\n<p>During the fiscal year ending December 31, 2025, the company's operating revenue saw substantial growth compared to the prior year. This core growth was primarily driven by two factors. First, following its market approval in July 2025, the company's Class 1 new drug Anweida® (product code: TPN171), used for treating male erectile dysfunction, demonstrated significant market promotion and sales effectiveness, leading to rapid revenue growth. Second, the License-out project for the respiratory syncytial virus (RSV) infection indication of the VV116 dry suspension reached a milestone, resulting in the successful receipt of a milestone payment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1166352107","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166352107","pubTimestamp":1774972704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B","BK1191":"制药"},"translate_title":"VIGONVITA-B公布2025财年业绩：股东亏损扩大至3.56亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to the previous year. However, the loss attributable to the company's owners was 356 million yuan, widening by 68.3% year-on-year. The basic loss per share was 2.33 yuan.\nDuring the fiscal year ending December 31, 2025, the company's operating revenue saw substantial growth compared to the prior year. This core growth was primarily driven by two factors. First, following its market approval in July 2025, the company's Class 1 new drug Anweida® (product code: TPN171), used for treating male erectile dysfunction, demonstrated significant market promotion and sales effectiveness, leading to rapid revenue growth. Second, the License-out project for the respiratory syncytial virus (RSV) infection indication of the VV116 dry suspension reached a milestone, resulting in the successful receipt of a milestone payment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166352107","isCrawlerRequest":true}